Quality of life in patients with myelodysplastic syndromes

Cancer Treatment Reviews

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Schuler, U ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Darbepoetin; Decitabine; Deferasinox; Erythropoietin; Haemochromatosis; Lenalidomide; Myelodysplastic syndromes; Quality of life

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEFERASINOX; DEFEROXAMINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; IRON CHELATING AGENT; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CORRELATION ANALYSIS; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL STRESS; ERYTHROPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON CHELATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; SOCIAL INTERACTION; SYMPTOMATOLOGY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 35848942162     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.008     Document Type: Article

References (40)

1. Bullinger M., and Hasford J. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials 12 (1991) 91S-105S
2. Aaronson N.K., Bullinger M., and Ahmedzai S. A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 111 (1988) 231-249
3. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
4. Cella D.F., Tulsky D.S., Gray G., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
5. Power M., Harper A., and Bullinger M. The World Health Organization WHOQOL-100: tests of the universality of Quality of Life in 15 different cultural groups worldwide. Health Psychol 18 (1999) 495-505
6. Cella D., Hahn E.A., and Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11 (2002) 207-221
7. Herschbach P. The "Well-being paradox" in quality-of-life research (Article in German). Psychother Psychosom Med Psychol 52 (2002) 141-150
8. Kallich J., McDermott A., Xu X., Fayers P., and Cella D. The relationship between patient knowledge of hemoglobin levels and health-related quality of life. Qual Life Res 15 (2006) 57-68
9. Stalfelt A.M., Brodin H., Pettersson S., and Eklof A. The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res 27 (2003) 481-488
10. Stalfelt A.M., Brodin H., Pettersson S., and Eklof A. The final phase in acute myeloid leukaemia (AML): A study of cause of death, place of death and type of care during the last week of life. Leuk Res 25 (2001) 673-680
11. Thomas M.L., Heptinstal K., and Hassan A. The impact of myelodysplastic syndromes on patients' lives. Blood (2005) 106
12. Thomas M.L., Heptinstal K., and Hassan A. The importance of the patient-physician relationship in myelodysplastic syndromes. Blood (2005) 106 [abstract 1340]
13. Randall T.C., and Wearn A.M. Receiving bad news: Patients with haematological cancer reflect upon their experience. Palliat Med 19 (2005) 594-601
14. Rich T., Innominato P.F., Boerner J., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11 (2005) 1757-1764
15. Meyers C.A., Albitar M., and Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104 (2005) 788-793
16. Hsu H.C., Lee Y.M., Tsai W.H., et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 63 (2002) 64-69
17. Tefferi A. Iron chelation therapy for myelodysplastic syndrome: If and when. Mayo Clin Proc 81 (2006) 197-198
18. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87 (2002) 1286-1306
19. Musto P., Lanza F., Balleari E., et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128 (2005) 204-209
20. Balleari E., Rossi E., Clavio M., et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 85 (2006) 174-180
21. Spiriti M.A., Latagliata R., Niscola P., et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84 (2005) 167-176
22. Stasi R., Abruzzese E., Lanzetta G., Terzoli E., and Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16 (2005) 1921-1927
23. Thomas M.L., Kim H., Miller K., et al. The use of erythropoietin inmyelodysplastic syndromes (MDS): impact on fatigue and quality of life. Leuk Res Suppl 29 (2005) S52 [abstract p75]
24. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 (2003) 1037-1046
25. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
26. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104 (2004) 321-327
27. Jadersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., and Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106 (2005) 803-811
28. Varkonyi J, Demeter J, Tordai A, Andrikovics H. The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol 2006.
29. Speletas M., Kioumi A., Mandala E., et al. Prevalence of hemochromatosis gene (HFE) mutations in Greek patients with myelodysplastic syndromes. Acta Haematol 110 (2003) 53-54
30. Varkonyi J., Tarkovacs G., Karadi I., et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 109 (2003) 64-67
31. Jensen P.D., Heickendorff L., Pedersen B., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94 (1996) 288-299
32. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
33. Kornblith A.B., Herndon J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20 (2002) 2441-2452
34. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
35. Broliden P.A., Dahl I.M., Hast R., Johansson B., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91 (2006) 667-670
36. Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., and Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101 6 (2003) 2156-2158
37. Steensma D.P., and Bennett J.M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81 (2006) 104-130
38. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
39. List A.F., Dewald G., Bennett J., et al. Hematologic and Cytogenetic (CTG) Response to Lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J Clin Oncol (2005) 23 [abstract 5]
40. Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 106 (2006) 2087-2094